JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
139.68
+0.18 (+0.13%)
As of 1:26PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close139.50
Open138.34
Bid139.44 x 800
Ask139.46 x 1800
Day's Range137.91 - 139.99
52 Week Range118.62 - 148.32
Volume2,774,964
Avg. Volume6,188,890
Market Cap374.731B
Beta (3Y Monthly)0.53
PE Ratio (TTM)277.70
EPS (TTM)0.50
Earnings DateOct 11, 2016 - Oct 17, 2016
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2018-08-27
1y Target Est145.63
Trade prices are not sourced from all markets
  • A Performance Overview of JNJ’s Consumer Business
    Market Realist38 minutes ago

    A Performance Overview of JNJ’s Consumer Business

    Johnson & Johnson’s (JNJ) Consumer segment consists of the baby care, beauty, oral care, OTC (over-the-counter), women’s health, and wound care businesses.

  • What’s Pfizer’s Current Valuation?
    Market Realist3 hours ago

    What’s Pfizer’s Current Valuation?

    In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).

  • Pfizer’s Dividends and Earnings Quality
    Market Realist4 hours ago

    Pfizer’s Dividends and Earnings Quality

    In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.

  • 10 S&P 500 Stocks to Buy for the Long Term
    Kiplinger5 hours ago

    10 S&P 500 Stocks to Buy for the Long Term

    The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance

  • Pfizer Reported Revenue Growth in Global Markets
    Market Realist6 hours ago

    Pfizer Reported Revenue Growth in Global Markets

    Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.

  • Motley Fool16 hours ago

    Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?

    How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.

  • Investing.com17 hours ago

    Intuitive Surgical Earnings miss, Revenue beats In Q3

    Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.

  • Pfizer’s Growth Rate and Estimates
    Market Realist21 hours ago

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

  • Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
    Zacks22 hours ago

    Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch

    Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.

  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realistyesterday

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.

  • Pfizer’s Market Cap and Shareholding Pattern
    Market Realistyesterday

    Pfizer’s Market Cap and Shareholding Pattern

    As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.

  • Analyzing Pfizer’s Stock Performance in October
    Market Realistyesterday

    Analyzing Pfizer’s Stock Performance in October

    Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.

  • Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018
    PR Newswireyesterday

    Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018

    NEW BRUNSWICK, N.J., Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock.  The dividend is payable on December 11, 2018 to shareholders of record at the close of business on November 27, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.

  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Motley Fool2 days ago

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.

  • They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more
    American City Business Journals2 days ago

    They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more

    After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.

  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of JNJ earnings conference call or presentation 16-Oct-18 12:30pm GMT

    Q3 2018 Johnson & Johnson Earnings Call

  • Investing.com2 days ago

    Abbott Labs Earnings, Revenue beat in Q3

    Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.

  • Stock Market News For Oct 17, 2018
    Zacks2 days ago

    Stock Market News For Oct 17, 2018

    Wall Street rebounded on Tuesday as stocks surged across the board due to strong third-quarter 2018 earnings results and impressive economic data.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...

  • Asian shares climb on strong US corporate earnings, data
    Associated Press3 days ago

    Asian shares climb on strong US corporate earnings, data

    SINGAPORE (AP) — Asian markets rose on Wednesday as robust U.S. corporate earnings and encouraging data assuaged worries about softening global growth.

  • TheStreet.com3 days ago

    The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18)

    "When the Fed bears are away, the stock bulls will play," Jim Cramer told his Mad Money viewers Tuesday, after the markets mounted an impressive relief rally. Cramer reminded viewers that a panic is a terrible thing to waste, which is why the smart money was buying into the recent declines and not selling out of fear.

  • The Wall Street Journal3 days ago

    [$$] Prescription Drugs Power Johnson & Johnson Results

    Johnson & Johnson reported higher revenue and profit for the third quarter, as improved pharmaceutical sales helped offset weakness in its medical-device business. Global sales of J&J’s cancer drugs, which include Zytiga for prostate cancer and blood-cancer treatments Darzalex and Imbruvica, jumped 36% for the quarter. “Our positive view on pharma is offset by ongoing challenges to the company’s medical device and consumer franchises,” JPMorgan analyst Chris Schott wrote in a research note.

  • The Wall Street Journal3 days ago

    [$$] Encouraging Test Results for Health-Care Giants

    Another round of strong earnings suggests that health care is living up to its reputation as a defensive industry. UnitedHealth Group and Johnson & Johnson, two industry heavyweights, demonstrated that with third-quarter results on Tuesday by topping analyst expectations on both the top and bottom line and increasing their full year profit guidance. UnitedHealth, the nation’s largest publicly traded health insurer, reported revenue of $56.5 billion and adjusted earnings of $3.41 a share.

  • STOCKS on the move: Netflix, Facebook, McDonald's, J&J, Home Depot, IBM
    Yahoo Finance Video2 days ago

    STOCKS on the move: Netflix, Facebook, McDonald's, J&J, Home Depot, IBM

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves.

  • Stocks can keep rallying as long as Fed doesn't keep push...
    CNBC Videos3 days ago

    Stocks can keep rallying as long as Fed doesn't keep push...

    Jim Cramer explains what led the market to soar on Tuesday after days of selling and says the strength can last if the Fed behaves accordingly.